| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Henry Ward Winship IV is Director at CHRW, with reported holdings spanning 2 companies. Henry Ward Winship IV's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $38.9M at current prices.
Our model assigns Henry Ward Winship IV a below-average insider score of 35/100, based on 3 past trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -24.9%.
Henry Ward Winship IV's largest disclosed position is in CHRW as Director, worth about $35.6M. The CHRW filings lean toward selling, a net 211 shares.
Henry Ward Winship IV has 33 Form 4 filings on record from March 2022 to September 2026, across 2 companies: Director at Bunge Global (BG), 2023–2026; Director at C. H. Robinson Worldwide (CHRW), 2022–2025.
The 35 reported transactions were 15 stock awards, 14 option or other derivative awards, 3 tax withholdings and 3 open-market sales.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $17K.
The largest open-market sale was 204 shares of CHRW at an average $82.32 on May 10, 2024, about $17K. Twelve months later CHRW was up 8%.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.